CK2 is known to negatively regulate apoptosis, and increased activity has been noted in many proliferating tissues and tumors, which lends promise as an anticancer drug target. CAY10578 is a potent inhibitor of CK2 and is ATP competitive, only minimally inhibiting the activities of other protein kinases.
